Innovative Protein Folding Predictions

A Revolutionary Breakthrough in Precision Medicine

Based on the leading science of Dr. Neil Cashman, our proprietary target discovery engine utilizes two computational discovery technologies, ProMIS™ and Collective Coordinates, to predict and identify toxic misfolded proteins implicated in the development and progression of neurodegenerative diseases.

About Our Science

A Growing Portfolio of Selective Antibody Therapeutics

Our portfolio leverages a revolutionary approach that enables the tailoring of therapeutic antibodies with a high degree of selectivity for the key drivers of multiple neurodegenerative diseases, including:

  • Alzheimer’s disease (AD)
  • Amyotrophic lateral sclerosis (ALS)
  • Parkinson’s disease (PD)
View Product Pipeline

Addressing Neurodegenerative Diseases Using Novel Biologic Products

We are ProMIS Neurosciences, a leading development-stage biotechnology company based in Toronto, Ontario and Cambridge, Massachusetts. Our large team of multidisciplinary experts is committed to the discovery and development of selective antibody therapies that combat neurodegenerative diseases at the source.

About Our Company

Latest News

ProMIS Neurosciences Announces Antibody Program for Schizophrenia Therapy and Recruitment of Dr. Carsten Korth to its Scientific Advisory Board

ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer’s Treatment

ProMIS Neurosciences to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

Stock Snapshot